Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial.

Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News. Please fill in the fields below to receive our news.

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to USD 29.8 billion in the first nine months of 2024.

Welcome to Novo Nordisk's U.S. news and media hub. Here you can access our news releases, social media accounts, media contacts, sign up for email alerts, ...

Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg ...

GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

6 сент. 2024 г. · Novo Nordisk today presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable.

#PRESS: Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024.

Get the latest insights on Novo Nordisk A/S Common Stock (NVO) with press releases and corporate news to help you in your trading and investing decisions.